174 results on '"Sleen, Yannick"'
Search Results
2. Effects of ageing and frailty on circulating monocyte and dendritic cell subsets
3. Effect of DMARDs on the immunogenicity of vaccines
4. Risk loci involved in giant cell arteritis susceptibility: a genome-wide association study
5. Impaired IL-6-induced JAK-STAT signaling in CD4+ T cells associates with longer treatment duration in giant cell arteritis
6. Frailty is related to serum inflammageing markers: results from the VITAL study
7. Disease stratification in GCA and PMR: state of the art and future perspectives
8. Humoral SARS–CoV‐2 Vaccine Responses in Patients With Giant Cell Arteritis and Polymyalgia Rheumatica: Decay After Primary Vaccination and Effects of the Booster
9. Cytokine producing B-cells and their capability to polarize macrophages in giant cell arteritis
10. Angiopoietin-2/-1 ratios and MMP-3 levels as an early warning sign for the presence of giant cell arteritis in patients with polymyalgia rheumatica
11. mRNA-1273 vaccination induces polyfunctional memory CD4 and CD8 T cell responses in patients with solid cancers undergoing immunotherapy or/and chemotherapy.
12. Altered Plasma Levels and Tissue Expression of Fibroblast Activation Protein Alpha in Giant Cell Arteritis.
13. Disease stratification in giant cell arteritis to reduce relapses and prevent long-term vascular damage
14. Risk loci involved in giant cell arteritis susceptibility: a genome-wide association study
15. Multiple vaccine comparison in the same adults from the VITAL study reveals vaccine-specific and age-related humoral response patterns.
16. A randomized phase I/II safety and immunogenicity study of the Montanide-adjuvanted SARS-CoV-2 spike protein-RBD-Fc vaccine, AKS-452
17. Frailty is related to serum inflammageing markers: results from the VITAL study
18. Clonal haematopoiesis and UBA1 mutations in individuals with biopsy-proven giant cell arteritis and population-based controls
19. Effects of ageing and frailty on circulating monocyte and dendritic cell subsets
20. Humoral SARS–CoV‐2 Vaccine Responses in Patients With Giant Cell Arteritis and Polymyalgia Rheumatica: Decay After Primary Vaccination and Effects of the Booster
21. Aberrant phenotype of circulating antigen presenting cells in giant cell arteritis and polymyalgia rheumatica
22. Indication of Activated Senescence Pathways in the Temporal Arteries of Patients With Giant Cell Arteritis
23. Evidence for increased interferon type I activity in CD8+ T cells in giant cell arteritis patients
24. Biomarkers in the era of targeted therapy in giant cell arteritis and polymyalgia rheumatica: is it possible to replace acute-phase reactants?
25. Aberrant phenotype of circulating antigen presenting cells in giant cell arteritis and polymyalgia rheumatica
26. Humoral SARS–CoV‐2 Vaccine Responses in Patients With Giant Cell Arteritis and Polymyalgia Rheumatica: Decay After Primary Vaccination and Effects of the Booster
27. Metabolic features and glucocorticoid-induced comorbidities in patients with giant cell arteritis and polymyalgia rheumatica in a Dutch and Danish cohort
28. Humoral and cellular SARS-CoV-2 vaccine responses in patients with giant cell arteritis and polymyalgia rheumatica
29. Clonal haematopoiesis and UBA1 mutations in individuals with biopsy-proven giant cell arteritis and population-based controls.
30. Biomarkers in the era of targeted therapy in giant cell arteritis and polymyalgia rheumatica: is it possible to replace acute-phase reactants?
31. Contribution of pathogenic T helper 1 and 17 cells to bursitis and tenosynovitis in polymyalgia rheumatica
32. Subclinical giant cell arteritis in new onset polymyalgia rheumatica A systematic review and meta-analysis of individual patient data
33. Monocyte and macrophage heterogeneity in Giant Cell Arteritis and Polymyalgia Rheumatica:central in Pathology and a Source of Clinically Relevant Biomarkers
34. Immunogenicity and safety of COVID-19 vaccination in patients with primary Sjogren's syndrome
35. Immunogenicity and safety of COVID-19 vaccination in patients with primary Sjögren’s syndrome
36. Additional file 1 of Angiopoietin-2/-1 ratios and MMP-3 levels as an early warning sign for the presence of giant cell arteritis in patients with polymyalgia rheumatica
37. Comment on: Plasma Pyruvate Kinase M2 as a marker of vascular inflammation in Giant Cell Arteritis: Reply
38. Need and value of targeted immunosuppressive therapy in giant cell arteritis
39. Subclinical Giant Cell Arteritis in New Onset Polymyalgia Rheumatica: A Systematic Review and Meta-Analysis of Individual Patient Data
40. Atteinte de l’aorte dans l’artérite à cellules géantes
41. Dysregulated Glucose Metabolism and Dyslipidemia in GCA and PMR Patients at Diagnosis
42. A distinct subset of YKL-40 expressing macrophages drive tissue destruction and neovascularisation in giant cell arteritis
43. Plasma Pyruvate Kinase M2 as a marker of vascular inflammation in giant cell arteritis
44. A Distinct Macrophage Subset Mediating Tissue Destruction and Neovascularization in Giant Cell Arteritis: Implication of the YKL‐40/Interleukin‐13 Receptor α2 Axis
45. Functionally Heterogenous Macrophage Subsets in the Pathogenesis of Giant Cell Arteritis: Novel Targets for Disease Monitoring and Treatment
46. Comparison and validation of FDG-PET/CT scores for polymyalgia rheumatica
47. Plasma Pyruvate Kinase M2 as a marker of vascular inflammation in giant cell arteritis.
48. Aortic involvement in giant cell arteritis
49. Comparison and validation of FDG-PET/CT scores for polymyalgia rheumatica.
50. Distinct macrophage phenotypes skewed by local granulocyte macrophage colony‐stimulating factor (GM‐CSF) and macrophage colony‐stimulating factor (M‐CSF) are associated with tissue destruction and intimal hyperplasia in giant cell arteritis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.